Artículos con órdenes de acceso público - Pier Luigi ZinzaniMás información
TotalNIHGovernment of ItalyCancer Research UKAIRC Foundation for Cancer Research in ItalyNIHREuropean CommissionMRCLymphoma Research Foundation, USACCSWellcomeGobierno de EspañaCIHRV Foundation, USASNSFNHMRCKnut and Alice Wallenberg FoundationSwedish Research CouncilBlood Cancer UKFondazione CariploRCNBMBFSCFSCLUK Research & InnovationDamon Runyon Cancer Research Foundation
No disponibles en ningún lugar: 17
Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway
PP Piccaluga, M Rossi, C Agostinelli, F Ricci, A Gazzola, S Righi, ...
Leukemia 28 (8), 1687-1697, 2014
Órdenes: Government of Italy
Prognostic models for primary mediastinal (thymic) B‐cell lymphoma derived from 18‐FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group …
L Ceriani, M Martelli, A Conconi, PL Zinzani, AJM Ferreri, B Botto, ...
British Journal of Haematology 178 (4), 588-591, 2017
Órdenes: Cancer Research UK
Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine
C Pellegrini, V Stefoni, B Casadei, R Maglie, L Argnani, PL Zinzani
Annals of hematology 93, 1853-1857, 2014
Órdenes: Wellcome Trust
Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab …
PL Zinzani, R Chen, P Armand, NA Johnson, P Brice, J Radford, V Ribrag, ...
Leukemia & lymphoma 61 (4), 950-954, 2020
Órdenes: US National Institutes of Health
NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY
SM Ansell, PJ Bröckelmann, G von Keudell, HJ Lee, A Santoro, ...
Hematological Oncology 39, 2021
Órdenes: Canadian Cancer Society
Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma
B von Tresckow, M Fanale, KM Ardeshna, R Chen, J Meissner, ...
Leukemia & lymphoma, 2019
Órdenes: National Institute for Health Research, UK
Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial
L Zanoni, A Broccoli, A Lambertini, C Pellegrini, V Stefoni, F Lodi, C Fonti, ...
European Journal of Nuclear Medicine and Molecular Imaging 46, 1661-1671, 2019
Órdenes: Government of Italy
Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non‐Hodgkin B‐cell lymphomas
JM Sancho, B Navarro, JA Soler Campos, JP de Oteyza, ...
European Journal of Haematology 104 (5), 499-508, 2020
Órdenes: Gobierno de España
Nivolumab plus brentuximab vedotin for relapsed/refractory primary mediastinal large B‐cell lymphoma: extended follow‐up from the phase 2 checkmate 436 study
PL Zinzani, A Santoro, G Gritti, P Brice, PM Barr, J Kuruvilla, ...
Hematological Oncology 39, 2021
Órdenes: Canadian Cancer Society
Genetic characterization of primary mediastinal B-cell lymphoma: pathogenesis and patient outcomes
D Noerenberg, F Briest, C Hennch, K Yoshida, R Hablesreiter, Y Takeuchi, ...
Journal of Clinical Oncology 42 (4), 452-466, 2024
Órdenes: Knut and Alice Wallenberg Foundation, Swedish Research Council, European …
CAMIDANLUMAB TESIRINE EFFICACY AND SAFETY IN AN OPEN‐LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS (PTS) WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)
PL Zinzani, C Carlo‐Stella, M Hamadani, AF Herrera, SM Ansell, ...
Hematological Oncology 39, 2021
Órdenes: National Health and Medical Research Council, Australia
Novel methods to improve the efficiency of radioimmunotherapy for non-Hodgkin lymphoma
M Eskian, MH Khorasanizadeh, PL Zinzani, TM Illidge, N Rezaei
International Reviews of Immunology 38 (2), 79-91, 2019
Órdenes: National Institute for Health Research, UK
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial
A Tedeschi, AM Frustaci, A Condoluci, M Coscia, R Chiarle, PL Zinzani, ...
The Lancet Oncology, 2024
Órdenes: European Commission
Allogeneic stem cell transplantation is capable of healing a case of bone marrow aplasia following CAR-T cell therapy in a lymphoma patient
G Lolli, M Ursi, M Dicataldo, B Casadei, G Storci, L Argnani, F Bonifazi, ...
Leukemia & Lymphoma 63 (12), 3012-3014, 2022
Órdenes: Government of Italy
Gut microbiome in DLBCL patients undergoing first‐line R‐CHOP regimen—The Oncopassport Study.
V Stefoni, L Argnani, B Casadei, G Musuraca, L Nanni, C Pellegrini, ...
Hematological Oncology 41, 2023
Órdenes: Cancer Research UK
TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+ CHP) Versus CHOP in Frontline Treatment of Patients …
S Iyer, L Trümper, OA O’Connor, B Pro, T Illidge, R Advani, NL Bartlett, ...
Clinical Lymphoma Myeloma and Leukemia 21, S411, 2021
Órdenes: US National Institutes of Health
HEALTH‐RELATED QUALITY OF LIFE AMONG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL) IN A PHASE 3 STUDY OF PEMBROLIZUMAB VERSUS BRENTUXIMAB VEDOTIN
PL Zinzani, M Raut, T Saretsky, R Ramchandren, A Santoro, ...
Hematological Oncology 39, 2021
Órdenes: Canadian Cancer Society
Disponibles en algún lugar: 118
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma
AK Gopal, BS Kahl, S De Vos, ND Wagner-Johnston, SJ Schuster, ...
New England Journal of Medicine 370 (11), 1008-1018, 2014
Órdenes: US National Institutes of Health
Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma
R Chen, PL Zinzani, MA Fanale, P Armand, NA Johnson, P Brice, ...
Journal of Clinical Oncology 35 (19), 2125-2132, 2017
Órdenes: US National Institutes of Health
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
A Younes, A Santoro, M Shipp, PL Zinzani, JM Timmerman, S Ansell, ...
The lancet oncology 17 (9), 1283-1294, 2016
Órdenes: US National Institutes of Health, National Institute for Health Research, UK …
La información de publicación y financiación se determina de forma automática mediante un programa informático